Dr. Elizabeth A White's lab at Tufts University focuses on understanding how high-risk human papillomavirus (HPV) manipulates host cell signaling to promote persistent infections and contribute to cancer development. By studying the viral proteins E6 and E7, the lab explores their roles in cellular transformation, including how they disrupt signaling pathways that normally regulate cell growth and differentiation. This research aims to uncover mechanisms that could lead to new therapeutic strategies for HPV-related cancers.

Dr. Chuo Chen's lab at UT Southwestern Medical Center focuses on developing new drugs to treat cancer by targeting a specific cell signaling pathway known as Wnt/-catenin. This pathway is often dysfunctional in many cancers, particularly colorectal cancer, which affects thousands of people each year. The lab utilizes innovative chemical strategies and protein studies to understand how certain enzymes can control cancer growth and offer potential treatment solutions.

Jun Wu's research lab at UT Southwestern Medical Center focuses on innovative techniques to study brain development and evolution using interspecies models. The team employs a groundbreaking method called blastocyst complementation to introduce rat brain tissue into mice, allowing for the investigation of how different species' brains develop and function together. This research has significant implications for understanding neurological processes and potentially ethical considerations concerning human brain studies.

Dr. Mingyi Xie's lab at the University of Florida focuses on understanding how specific small RNAs called microRNAs are regulated in T-cell acute lymphoblastic leukemia (T-ALL). They are investigating a novel mechanism where mRNA can degrade microRNAs, which could lead to new strategies for treating leukemia and overcoming resistance to current therapies. The lab's work could provide insights into gene regulation and potential therapeutic approaches for cancer treatment.

Dr. Itai Yanai's lab at New York University School of Medicine focuses on understanding how cancer cells adapt to treatment, specifically studying the transition from lung adenocarcinoma to squamous cell carcinoma in response to specific drugs like adagrasib. By exploring molecular mechanisms and chromatin regulators involved in this process, the lab aims to uncover new therapeutic strategies to counteract drug resistance in lung cancer. Their research combines advanced genetic screening techniques with mouse and organoid models to identify vulnerabilities in cancer cells.

Dr. Licy Yanes Cardozo's lab focuses on understanding the relationship between obesity and blood pressure regulation in women with Polycystic Ovary Syndrome (PCOS). They investigate how hormonal imbalances and adipose tissue function can lead to insulin resistance and cardiovascular issues. Through their research, they aim to find new treatments to help manage these health complications related to PCOS.

Dr. Kenichi Yokoyama's lab at Duke University focuses on understanding how enzymes that utilize metals (metalloenzymes) work, particularly in the creation of essential compounds found in nature. They study the way these enzymes help synthesize complex molecules and investigate how to block the action of key fungal enzymes to combat fungal infections. Overall, their research aims to reveal new ways to develop drugs that can help treat significant health issues caused by pathogenic fungi.

Dr. Peng Zhao's lab at the University of Texas Health Science Center focuses on understanding how liver injury occurs in nonalcoholic steatohepatitis (NASH), a serious liver disease that can lead to cirrhosis and liver cancer. By exploring the role of specific proteins and cellular processes, the lab aims to identify new therapeutic approaches to treat NASH and improve liver health. This research is essential for developing effective strategies to combat this growing public health issue.

Dr. Pei Zhou's lab at Duke University focuses on developing new antibiotics to combat multidrug-resistant Gram-negative bacteria, which are increasingly difficult to treat. The lab specifically studies LpxH, an enzyme critical for bacterial survival, and aims to create inhibitors that can effectively treat infections caused by resistant pathogens like E. coli and Klebsiella pneumoniae. Their innovative approach looks to exploit unexploited pathways in bacteria, potentially leading to breakthroughs in antibiotic therapy.

Dr. Wenge Zhu's research lab at George Washington University focuses on understanding and overcoming resistance to breast cancer therapies. The lab investigates how specific molecular pathways influence both CDK4/6 inhibitor and aromatase inhibitor resistance, aiming to develop novel therapeutic strategies for patients with advanced breast cancer. By studying the roles of specific proteins and gene mutations, Dr. Zhu's team seeks to improve treatment outcomes for affected patients.

Dr. Yazhen Zhu's lab focuses on improving the early detection of hepatocellular carcinoma (HCC), a severe type of liver cancer. The team is developing a novel assay that uses advanced chemistry to isolate and quantify specific particles released by tumors, which could serve as better biomarkers. This approach aims to enhance the accuracy of current diagnostic methods, ultimately allowing for earlier and more successful interventions for patients at risk of HCC.